We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack (ABC-AVC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00479518
First Posted: May 28, 2007
Last Update Posted: February 27, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University Hospital, Tours
May 25, 2007
May 28, 2007
February 27, 2017
March 2007
April 2014   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00479518 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack
Prognostic Value of Cardiac and Renal Markers in the Acute Phase of Ischemic Stroke or Transient Ischemic Attack :Albuminuria-Brain Natriuretic Peptide-Cystatine C in Stroke
Patients with stroke or transient ischemic attack (TIA) are at high risk of poor outcome, recurrence of cardiovascular events or vascular death.Until now, no reliable predictive biological marker could be identified in the acute phase of stroke.We hypothese that, in the acute phase of ischemic stroke or TIA, the increase of cardiac ( brain natriuretic peptide, BNP) or renal markers (albuminuria, cystatin C)might predict recurrence of cardiovascular events or vascular death. We want to assess which one of these markers has the best prognosis value , in a prospective study of 300 stroke patients followed during 3 years.

Patients with ischemic stroke or TIA will be included in the 48 hours following the onset of symptoms, in 3 university hospitals.For each patient will be collected

  • 1 blood sample for the BNP measure in pg/ml
  • 1 blood sample for the Cystatin C measure in mg/l
  • 2 urinary samples to measure the albumine/creatinine ratio, at inclusion and 5 days after the inclusion, and to study the variation of albuminuria in micrograms/min.

The clinical follow-up will be organized during 3 years. The following events will be notified: poor outcome (defined with the Barthel and Rankin scores), recurrence of cardiovascular or cerebrovascular events, vascular death.

After adjustment on the main clinical prognosis factors, we want to determine wich one of these markers has the best prognosis significance and allows to identify in the acute phase the "high-risk" patients, in order to intensify individual treatment and secondary prevention.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Blood Urine
Non-Probability Sample
Patient with Ischemic stroke or TIA
  • Ischemic Stroke
  • Transient Ischemic Attack
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
159
February 2017
April 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ischemic stroke or TIA in the first 48 hours following the onset of symptoms

Exclusion Criteria:

  • Patient unable to give an informed consent
  • Urinary sample impossible to collect
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00479518
PHRI06-IB Cohorte ABC-AVC
No
Not Provided
Not Provided
University Hospital, Tours
University Hospital, Tours
Not Provided
Principal Investigator: BONNAUD Isabelle, MD Service de Neurologie / CHRU de Tours
University Hospital, Tours
February 2017